Sign in to view content

Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics

David R Lally, MD

Video
Published 2021

Related

Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years
Ehsan Rahimy, MD
Annual Meeting Talks
2022
Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Updates from the Field
2024
Beyond Complement: A Novel FAS Inhibition Approach for Neuroprotection in GA
Vaidehi S. Dedania, MD
Updates from the Field
2024

Category: AMD-Non-Neovascular

See more